Insulin Loaded Orally Dissolved Films (Insulin-ODF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01446120|
Recruitment Status : Unknown
Verified October 2011 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : October 5, 2011
Last Update Posted : October 5, 2011
This study is assessing the pharmacokinetics efficacy and of Insulin loaded Orally Dissolved Films (insulin-ODF) treatment. The Insulin-ODF is attached to the inner tissue of the chick (buccal) , Releasing the insulin to the circulation, while the film is dissolved..
- The Cmax (Maximum Concentration of insulin in mg).
- Tmax (the time to Cmax in minutes)
- AUC (Area Under the Curve) of blood insulin levels during six hours of the trial.
- The glucose and C-peptide levels during six hours of the trial. (mg)
- The safety of the treatment in a descriptive manner by recording all adverse events in the study population.
Seven healthy volunteers will be randomly assigned to one of the following groups:
A. Insulin-ODF following treatment group; Or B. commercial NPH Insulin treatment.
The study is designed a crossover, in which each group is treated 3-7 days of washout.
The volunteer subjects will arrive to the clinic after eight hours fasting. Each subject will be examined by a physician, evaluating the elegibilities to the trial (i.e. inclusion and exclusion criteria).
An I.V catheter will be administrated assessing the Glucose, Insulin and C-peptide levels, ten minutes and five minutes before injecting the NPH Insulin or the Insulin-ODF.
Blood Insulin and glucose levels will be evaluated at baseline, and after the following time points: 15,30,60,90,120,150,180,210,240,270,300,330,360 minutes. C-peptide levels will be evaluated at baseline and after the following time points: 60,120,240, 360 minutes.
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: NPH-Insulin Injection Drug: Insulin loaded Orally Dissolved Films (insulin-ODF||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||7 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Experimental: Insulin loaded Orally Dissolved Films (insulin-ODF)||Drug: Insulin loaded Orally Dissolved Films (insulin-ODF|
|Active Comparator: Human Insulin Specific RIA Kit <5uCi||Drug: NPH-Insulin Injection|
- Blood InsulinTo assess the Cmax , Tmax and AUC (Area Under the Curve) of blood insulin level during six hours of the trial.
- glucose and C-peptide levelsEvaluating the glucose and C-peptide levels during six hours of the trial.
- hypoglycemia and irritation.All the examinations will be done in the presence of a physician along with a medical assistant. Hypoglycemia and irritation are the main adverse event that we anticipate in this study. In any such event the proper reporting and treatment will be administrated, while these subjects will be followed up for a further 1 month